Approximately 15+ key companies are developing Anti-CD19 Antibody. The companies with their Anti-CD19 Antibody-drug candidates in the most advanced stage include Viela Bio, ADC Therapeutics, Amgen, Morphosys and Xencor.

DelveInsight’s “Anti-CD19 Antibody Pipeline Insight” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Anti-CD19 Antibody pipeline landscapes. It comprises Anti-CD19 Antibody pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Anti-CD19 Antibody therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Anti-CD19 Antibody pipeline products. 

 

Some of the key takeaways of the Anti-CD19 Antibody Pipeline Report  

• Notable companies such as TG Therapeutics, Merck kGaA, Generium Pharmaceutical, Sanofi, Incyte Corporation, Amgen, Viela Bio, and others are developing potential drug candidates to boost the Anti-CD19 Antibody treatment scenario. 
• In April 2021, Incyte and MorphoSys announced the first patient had been dosed in the placebo-controlled Phase 3 inMIND study evaluating the efficacy and safety of tafasitamab or placebo in combination with lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL).
• In March 2021, Amgen reported positive data from the Phase III study of BLINCYTO (blinatumomab) in paediatric patients with high-risk first-relapse B-cell precursor acute lymphoblastic leukaemia (B-ALL).
• In February 2021, Viela Bio announced additional positive results with UPLIZNA (inebilizumab-cdon) in patients with Neuromyelitis Optica Spectrum Disorder at the ACTRIMS 2021 Forum.
• In November 2020, Xencor, MorphoSys and Incyte announced a clinical collaboration to investigate the combination of tafasitamab, plamotamab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), first-line DLBCL, and relapsed or refractory follicular lymphoma (FL).
• In June 2020, inebilizumab received its first global approval in the USA for the Neuromyelitis Optica Spectrum Disorder (NMOSD) treatment in adult patients who are seropositive for immunoglobulin G autoantibodies against aquaporin-4 (AQP4-IgG). The drug is also undergoing clinical evaluation for kidney transplant desensitisation, myasthenia gravis, and IgG4-related disease.

 

 

Get an overview of pipeline landscape @ Anti-CD19 Antibody Clinical Trials Analysis

 

Anti-CD19 Antibody, a cluster of differentiation 19 (CD19), is a cell surface molecule expressed on B- lineage cells and follicular dendritic cells. CD19 comprises two extracellular immunoglobulin-like domains and an extensive cytoplasmic tail. It functions as a positive regulator of B-cell receptor signalling in conjunction with CD21 and CD81.  CD19 is expressed throughout B-cell development and plays a critical role in maintaining the balance between humoral, antigen-induced immune response and tolerance induction.

 

Anti-CD19 Antibody Emerging Drugs

• Inebilizumab: Viela Bio

Inebilizumab is a humanised monoclonal antibody designed to target and deplete CD19-expressing B cells through antibody-dependent cell-mediated cytotoxicity. 

 

Research and Development Myasthenia Gravis Phase III

NCT04524273: In August 2020, Viela Bio initiated a randomised, double-blind, multicenter, placebo-controlled Phase 3 study with an open-label period to assess the efficacy and safety of Inebilizumab in adults with Myasthenia Gravis. This study is a phase 3, randomised, double-blind, placebo-controlled study conducted at approximately 100 study sites. About 252 subjects (172 AChR-Ab+ and 80 MuSK-Ab+) will be enrolled. The study is estimated to get completed by December 2024 with 252 registered participants.

IgG4-Related Disease  Phase III NCT04540497: In October 2020, Viela Bio initiated a Phase 3, randomised, double-blind, multicenter, and placebo-controlled study of Inebilizumab efficacy and safety in IgG4-Related Disease. This study focuses on defining the effectiveness and safety of Inebilizumab for the prevention of flare of IgG4-related disease (IgG4-RD). The study is estimated to get completed by June 2024 with 160 enrolled participants.

 

For further information, refer to the detailed report @ Anti-CD19 Antibody Pipeline Therapeutics 

 

Scope of Anti-CD19 Antibody Pipeline Drug Insight    

• Coverage: Global 
• Major Players: 15+  Key Players
• Prominent Players: TG Therapeutics, Merck kGaA, Generium Pharmaceutical, Sanofi, Incyte Corporation, Amgen, Viela Bio, and many others.   
• Key Drugs Profiles: 15+ Products
• Phases:  
• Mechanism of Action:
• Molecule Types:   
• Route of Administration:
• Product Types:

• Anti-CD19 Antibody Therapies Late-stage (Phase III)  
• Anti-CD19 Antibody Therapies Mid-stage (Phase II)
• Anti-CD19 Antibody Therapies Early-stage (Phase I) 
• Anti-CD19 Antibody Pre-clinical stage and Discovery candidates   
• Discontinued and Inactive candidates 

• CD-19 Antagonist

• Antibody

• Intravenous  
• Parenteral

• Monotherapy
• Combination
• Mono/Combination 

 

Key Questions regarding Current Anti-CD19 Antibody Treatment Landscape and Emerging Therapies Answered in the Pipeline Report  

• What are the current options for Anti-CD19 Antibody treatment?
• How many companies are developing therapies for the treatment of Anti-CD19 Antibody? 
• How many are Anti-CD19 Antibody emerging therapies in the early-stage, mid-stage, and late development stages to treat Anti-CD19 Antibody?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the Anti-CD19 Antibody market? 
• Which are the dormant and discontinued products and the reasons for the same?
• What is the unmet need for current therapies for the treatment of Anti-CD19 Antibody?  
• What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Anti-CD19 Antibody therapies? 
• What are the critical designations that have been granted for the emerging therapies for Anti-CD19 Antibody? 
• How many patents are granted and pending for the emerging therapies to treat Anti-CD19 Antibody?   

 

Table of Contents

1	Anti-CD19 Antibody Report Introduction
2	Anti-CD19 Antibody Executive Summary
3	Anti-CD19 Antibody Overview
4	Anti-CD19 Antibody – DelveInsight’s Analytical Perspective In-depth Commercial Assessment
5	Anti-CD19 Antibody Pipeline Therapeutics
6	Anti-CD19 Antibody Late Stage Products (Phase III)
6.1	Inebilizumab : Viela Bio
7	Anti-CD19 Antibody Mid Stage Products (Phase II)
7.1	Coltuximab ravtansine : Sanofi
8	Anti-CD19 Antibody Early Stage Products (Phase I/II)
8.1	GNR-084: Generium Pharmaceutical
9	Anti-CD19 Antibody Early Stage Products (Phase I)
9.1	DI-B4: Merck KGaA
10	Anti-CD19 Antibody Therapeutic Assessment
11	Anti-CD19 Antibody Inactive Products
12	Company-University Collaborations (Licensing/Partnering) Analysis
13	Anti-CD19 Antibody Key Companies
14	Anti-CD19 Antibody Key Products
15	Anti-CD19 Antibody Unmet Needs
16	Anti-CD19 Antibody Market Drivers and Barriers
17	Anti-CD19 Antibody Future Perspectives and Conclusion
18	Anti-CD19 Antibody Analyst Views
19	Appendix
20	About DelveInsight

 

Get a customised pipeline report @ Anti-CD19 Antibody Drugs Pipeline Report

 

Other Trending Reports:

Hip Replacement Devices Market

Hip Reconstruction/Replacement Devices Market Insights, Competitive Landscape and Market Forecast-2027 report delivers an in-depth understanding of Hip Reconstruction/Replacement Devices and the historical and forecasted Hip Reconstruction/Replacement Devices market trends in the 7MM.

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Portfolio Management Services to understand the competencies, leverage strengths to prioritise strategic goals and understand the market’s current needs.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/anti-cd19-antibody-pipeline-insight